Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for scientists. T cells, which are the frontline warriors in the battle against ...

The Will County Community Health Center has added an Infectious Disease Clinic to its list of medical services, offering STI ...

Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Roorkee have uncovered a crucial regulatory mechanism in Acinetobacter baumannii -- a highly drug-resistant superbug ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

New insights into what causes the painful and disruptive symptoms of urinary tract infections (UTIs) could offer hope for improved treatment. UTIs are one of the most prevalent bacterial infections ...